-
Mashup Score: 6Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study - 8 hour(s) ago
We have found several additional loci associated with giant cell arteritis, highlighting the crucial role of angiogenesis in disease susceptibility. Our study represents a step forward in the translation of genomic findings to clinical practice in giant cell arteritis, proposing new treatments and a method to measure genetic predisposition to this vasculitis.
Source: www.thelancet.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 11
AbstractObjectives. To assess the frequency and characteristics of severe relapse in patients with GCA in a real-life setting.Methods. In a monocentric dat
Source: academic.oup.comCategories: General Medicine News, RheumatologyTweet-
In 530 #GCA pts, relapses seen in 46%; but severe relapse (ischemi/aortic events) in 3%. Severe GCA relapse pts more likely to be younger at Dx(P=0.02), w/ more limb claudication(< 0.0001), fewer GCA-related cranial Sxs (<0.0001); but not higher mortality https://t.co/k7wgU6oMcn https://t.co/BKOfGmZ27u
-
-
Mashup Score: 22
AbstractObjectives. To assess the frequency and characteristics of severe relapse in patients with GCA in a real-life setting.Methods. In a monocentric dat
Source: academic.oup.comCategories: General Medicine News, RheumatologyTweet-
In 530 #GCA pts, relapses seen in 46%; but severe relapse (ischemi/aortic events) in 3%. Severe GCA relapse pts more likely to be younger at Dx(P=0.02), w/ more limb claudication(< 0.0001), fewer GCA-related cranial Sxs (<0.0001); but not higher mortality https://t.co/qyUpepmryA https://t.co/MJ9kAKl62r
-
-
Mashup Score: 33Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis - 18 day(s) ago
− Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg)…
Source: www.prnewswire.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 51Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis - 22 day(s) ago
− Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg)…
Source: www.prnewswire.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 29
A prediction tool for giant cell arteritis (the HAS-GCA score), combining SGCAPS and the halo count, reliably confirms and excludes giant cell arteritis from giant cell arteritis mimics in fast-track clinics. These findings require confirmation in an independent, multicentre study.
Source: www.thelancet.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 3Patients with higher apolipoprotein A-I levels at greater risk for giant cell arteritis - 2 month(s) ago
Patients who eventually developed giant cell arteritis demonstrated significantly higher levels of apolipoprotein A-I at baseline, according to population-based data published in Arthritis Research & Therapy. “Previous work from our group indicated that obesity and diabetes were associated with a reduced risk for giant cell arteritis, and that there was also an inverse relation with
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 2Glucocorticoid discontinuation rate and risk factors for relapses in a contemporary cohort of patients with giant cell arteritis - 2 month(s) ago
The rates of relapses and therapy discontinuation in patients with giant cell arteritis (GCA) in the modern therapeutic era have not been defined. We aimed to evaluate the glucocorticoid (GC) discontinuation rate and the factors associated with relapses …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 4Halo sign on temporal artery ultrasound versus temporal artery biopsy for giant cell arteritis - Pouncey, AL - 2024 | Cochrane Library - 3 month(s) ago
Collapse all Expand all Background Giant cell arteritis (GCA) is a systemic, inflammatory vasculitis primarily affecting people over the age of 50 years. GCA is treated as a medical emergency due to the potential for sudden, irreversible visual loss. Temporal artery biopsy (TAB) is one of the five criteria of the American College of Rheumatology (ACR) 1990 classification, which is used to…
Source: www.cochranelibrary.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 31The IL-17 pathway as a target in giant cell arteritis - 4 month(s) ago
The network of IL-17 cytokines is considered a key component of autoimmune and inflammatory processes. Blocking IL-17 showed great success in psoriasis as well as psoriatic arthritis, and in patients with axial spondyloarthritis. Secukinumab is one of the approved IL-17A inhibitors for these diseases and is now routinely used. In giant cell arteritis, a large vessel vasculitis, there is accumulating evidence for a pathogenic role of IL-17 and Th17 cells, which are part of the CD4+ T-cell subset. Giant cell arteritis occurs in individuals over 50 years of age and many have relative contraindications to glucocorticoid therapy, which today still represents the mainstay therapy. Despite the approval of tocilizumab, which targets the IL-6 receptor, a high demand for glucocorticoid-sparing agents remains that combine the effective suppression of the acute inflammation observed in giant cell arteritis with a safety profile that matches the needs of an older patient population. The first resul
Source: www.frontiersin.orgCategories: General Medicine News, General HCPsTweet
NEW RESEARCH—A genome-wide association study finds three novel risk loci involved in giant cell arteritis susceptibility https://t.co/3clTb4eetS #GCA @Sarah_L_Mackie https://t.co/ADJITxjDuG